4Martin-Llahi M, P6pin MN, Guevara M, et at. Terlip ressin and albumin vs albumin in patients with cirrho sis and hepatorenal syndrome: a randomized stud[J] Gastroenterology, 2008,134(5) : 1352-1359.
3Nguyen GC,Sergev DL,Thuluvath PJ. Nationwide increase in hospitalizations and hepatitis among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepa- tol, 2007,5:1092-1099.
4Schrier RW,Aloyo V,Bemardi M,et al. Peripheral arterial va- sodilation hypothesis :a proposal for the initiation of renal sodi- um and water retention in cirrhosis. Hepatology, 1988,8:1151- 1157.
5Ortega R,Gines P,Uriz J,et without albumin for patients al. Terlipressin therapy with and with hepatorenal syndrome:results of a prospective, nonrandomized study. Hepatology,2002,36 941-948.
6Angeli P,Volpin R,Gerunda G,et al. Reversal of type 1 hepa- torenal syndrome with the administration of midodrine and oc- treotide. Hepatology, 2004,40:55 -64.
7Virendra S,Souvik G,Baljinder S,et al. Noradrenaline vs. terli- pressin in the treatment of hepatorenal syndrome:A randomized study. J Hepatol,2012,56:1293-1298.
8Runyon BA,AASLD Practice Guidelines Committee. Manage- ment of adult patients with ascites due to cirrhosis:an update. Hepatology, 2009,49:2087 -2107.
9European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol, 2010,53:397-417.
10Salemo F,Gerbes A,Gines P,et al.Diagnosis,prevention and treatment of the hepatorenal syndrome in cirrhosis. Gut, 2007, 56:1310-1318.
